– USA, CA – Logix Biosciences, a biopharmaceutical company announced the addition of Amy Broidrick to its Board of Directors.
About Amy Broidrick
Her experience includes key roles in successfully commercializing numerous therapeutics, including marketing and launching blockbuster and specialty drugs such as Zetia, VYTORIN, and Celebrex.
Her global and US impact has marked Broidrick’s career. Amy Broidrick is serving as a strategic advisor to public and private US and international pharmaceutical and biotech companies and start-ups. In 2020 she was appointed as an independent, non-executive Director to the Board of Qualigen Therapeutics, a Nasdaq-listed clinical-stage biotechnology company focused on developing rare cancer therapeutics, where she later served as President, and Board Director from 2021-2023. Before Qualigen, she served as SVP and Head of Corporate Development at Viking Therapeutics responsible for US and global corporate and business development functions. Previously, she was VP and Head of Global Marketing Excellence and Business Innovation at EMD Serono, leading global and country brand and launch planning, and strategic transformation initiatives. From 2010 to 2012, Amy Broidrick was VP and Head of Marketing and Commercialization at Arena Pharmaceuticals, overseeing commercial planning of a first-in-class obesity drug candidate, and portfolio planning. She also held various roles at Merck & Co., including Global Brand Leader with P&L accountability, and leading new products marketing planning across brands and the pipeline for Asia Pacific.
“I am honored and excited to join the Board of Directors at Logix at this mission-critical time as the company develops its pipeline of precision therapeutics and companion diagnostics,” said Amy Broidrick.
Amy Broidrick holds a BA from Fairleigh Dickinson University, completed studies at Wroxton College in England, and post-graduate coursework at Fairleigh Dickinson.
About Logix Biosciences
Logix Biosciences is a biopharmaceutical company focused on discovering and developing precision therapeutics and companion diagnostics for allergy relief, protection against infectious diseases, and antimicrobial resistance.
For more information: https://logixbiosciences.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.